Scientists in Edinburgh are to benefit from £2.4 million funding award to find new ways to tackle brain tumours. Professors Margaret Frame and Valerie Brunton at the Cancer Research UK Edinburgh Centre have been given the Programme Award by the charity to carry out their research. Brain tumours are one of the hardest types of cancer to treat and survival has barely improved over the last 40...
Treatment-resistance in patients with one of the most aggressive types of blood cancer may be overcome by combining a new targeted drug called venetoclax with chemotherapy, researchers at the University of Glasgow have shown. Testing for activity of a cancer gene called ‘Trib2’ in patients with acute myeloid leukaemia (AML) could identify those people who would most benefit from this targeted treatment. AML is a...
A biopharmaceutical company developing novel anti-infectives has been awarded a £2.78 million grant to take forward clinical trials of a treatment discovered at the University of Strathclyde. The grant will help fund a Phase IIa trial of the oral formulation of MGB Biopharma’s lead investigational drug candidate, MGB-BP-3, for the treatment of the Clostridium difficile infection. Approximately 30 patients are expected to be enrolled into...
A collaborative partnership between academic and industrial institutions in the UK, Finland, Germany, Greece and the Netherlands, the network will be run from Glasgow’s Cancer Research UK Beatson Institute, one of the U.K.’s leading cancer research establishments. The four-year Translational Research Network for Prostate Cancer (TransPot) aims to provide a multidisciplinary training program, integrating cancer biology and systems medicine to enable young researchers to become...
Aberdeen, UK, 12th March 2018 – NovaBiotics Ltd (NovaBiotics), a clinical-stage anti-infectives biotechnology company, announces receipt of Fast Track Designation (FTD) for its cystic fibrosis (CF) therapy, Lynovex®, from the United States Food and Drug Administration (FDA). The FDA has granted Fast Track Designation for NovaBiotics‘ orally administered form of Lynovex® for the treatment of acute pulmonary exacerbations in CF. Lynovex® is a first-in-class dual...
Glasgow based Formedix has announced its partnership with The iMATCH (Innovate Manchester Advanced Therapy Centre Hub) consortium. The recently formed Manchester consortium, led by The Christie, has been awarded almost £7 million of funding, to advance a new generation of therapies for cancer, genetic and degenerative diseases. Manchester is one of only three centres in Britain awarded funding by Innovate UK, the government’s innovation agency, to coordinate a...